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Streptococcus pyogenes (group A Streptococcus) causes severe
invasive infections including scarlet fever, pharyngitis (streptococ-
cal sore throat), skin infections, necrotizing fasciitis (flesh-eating
disease), septicemia, erysipelas, cellulitis, acute rheumatic fever,
and toxic shock. The conversion from nonpathogenic to toxigenic
strains of S. pyogenes is frequently mediated by bacteriophage
infection. One of the key bacteriophage-encoded virulence factors
is a putative ‘‘hyaluronidase,’’ HylP1, a phage tail-fiber protein
responsible for the digestion of the S. pyogenes hyaluronan cap-
sule during phage infection. Here we demonstrate that HylP1 is a
hyaluronate lyase. The 3D structure, at 1.8-Å resolution, reveals an
unusual triple-stranded -helical structure and provides insight
into the structural basis for phage tail assembly and the role of
phage tail proteins in virulence. Unlike the triple-stranded -helix
assemblies of the bacteriophage T4 injection machinery and the
tailspike endosialidase of the Escherichia coli K1 bacteriophage
K1F, HylP1 possesses three copies of the active center on the
triple-helical fiber itself without the need for an accessory catalytic
domain. The triple-stranded -helix is not simply a structural
scaffold, as previously envisaged; it is harnessed to provide a
200-Å-long substrate-binding groove for the optimal reduction in
hyaluronan viscosity to aid phage penetration of the capsule.
crystal  enzyme  lyase  streptococcus  bacteriophage
S treptococcus pyogenes (group A Streptococcus) causes a widerange of acute infections in the respiratory tract and skin
with invasive infections causing the life-threatening ‘‘f lesh-
eating’’ disease, necrotizing fasciitis, and the pyrogenic exotoxin-
associated toxic shock syndrome (1). In 1927 it was demonstrated
that S. pyogenes could be converted from a noninfective to a
toxigenic state through the application of a soluble extract of
scarlet fever isolates (2), which was subsequently shown to
contain bacteriophage. Several of the virulence factors produced
by S. pyogenes strains are now known to be bacteriophage-
encoded. These factors include pyrogenic exotoxins A and C (3,
4), DNase (5), and ‘‘hyaluronidase’’ (6). Indeed, the involvement
of phage-encoded virulence factors is now known to be a feature
common to many bacterial pathogens (7, 8) with bacteriophage
implicated in genome rearrangement (9) and, in the case of
Streptococcus, interstrain transfer of pyrogenic exotoxin (Spe)
genes (5, 10, 11). Spes, notably virulence factors SpeC and SpeA,
are ‘‘superantigens’’ that directly cross-link the major histocom-
patibility complex class II on the antigen-presenting cells with T
cell receptors, stimulating between 5% and 30% of the total T
cell population (5, 12). The increased amounts of inflammatory
cytokines result in the symptoms of scarlet fever and, in some
cases, toxic shock (1, 12, 13). Spe genes are expressed at prophage
induction (5), and the simultaneous induction of SpeC and
prophage was shown to be mediated by a ‘‘soluble factor’’ by
coculturing streptococci with pharyngeal cells (14). The precise
events inducing conversion from lysogenic to a lytic cycle remain,
however, unclear.
The genome sequencing of S. pyogenes strain SF370, revealed
three full-length prophage sequences (15) belonging to the
Siphoviridae family of bacteriophage (-like bacteriophage with
long noncontractile tails). Of particular interest is the hyaluron-
idase ORF, HylP1, annotated among the tail fiber genes within
the SF370.1 prophage (Fig. 1a). The likely role of this hyaluron-
idase is to allow phage penetration of the streptococcal hyal-
uronic acid (HA) capsule (16) (Fig. 1b) during transfection. To
gain insight into the phage-mediated conversion to pathogenic-
ity, in particular the role of the putative tail-fiber hyaluronidase,
biochemical and structural analysis of HylP1 (from the only
prophage of S. pyogenes SF370 that has been shown to be
inducible, prophage SF370.1) was undertaken. We confirm that
HylP1 is in fact a hyaluronate lyase, catalyzing a -elimination
reaction as first proposed by Baker et al. (17) and not a
hyaluronan hydrolase. The 3D structure reveals a central triply
wound -helix on a protein 220 Å in length. All previous
observations of this unusual fold have been phage-tail proteins,
giving considerable credence to a similar role in phage SF370.1.
It is widely believed that the triple-stranded -helix (TSH)
motif is characteristic of structural proteins from viral tails, yet
in marked contrast to the triple-stranded -helical structures of
the bacteriophage T4 injection machine (18) and the phages
infecting the polysialic-acid-encapsulated human pathogen
Escherichia coli K1 (19), the catalytic center of HylP1 does not
reside on an accessory catalytic domain but on the triple-
stranded -helical core itself, whose organization may shed light
on the assembly of the Siphoviridae tail fibers themselves.
Experimental Procedures
Cloning, Overexpression, and Site-Directed Mutagenesis. The amino
sequence of HylP1 (AAK33657.1) was checked for the presence
and location of signal peptide cleavage sites by using the SignalP
3.0 server, (www.cbs.dtu.dkservicesSignalP) (20). The entire
coding sequence (CDS) hylP1 (SPy0701) was amplified from the
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genomic DNA of S. pyogenes SF370, American Type Culture
Collection 700294 (15). This procedure required a two-stage
process, because the 3 end of CDS hylP3 (SPy1445) is identical
to hylP1. The first set of primers used were 5-ATggCAAT-
CAATgggTCAAg-3 and 5-ggATCCCTATTTTTTTAgTAT-
gAg-3. The amplified product was cloned into pGEM-T Easy
(Promega) and designated pHylP1  5. The hylp1 ORF was
amplified from pHylP1  5 by using 5-CATATgAgT-
gAAAATATACCgCTg3- and 5-ggATCCCTATTTTTTTAg-
TATgAg-3 and cloned into pET28a (Novagen) on an NdeI–
BamHI fragment and designated pHylP1. The conditions used
for amplification were as specified for use with Platinum Pfx
DNA polymerase (Invitrogen). Plasmids pD137A and pY149A
were generated from pHylP1 by using the QuikChange site-






Production and Purification of HylP1 and Derivatives. N-terminally
hexahistidine-tagged HylP1 was produced through induction of
pHylP1-containing E. coli BL21 (DE3; Novagen) cultures grown
at 30°C. HylP1 was purified by means of affinity chromatography
using nickel-charged Sepharose chelating fast f low resin (GE
Healthcare, Chalfont St. Giles, U.K.), followed by gel filtration
using a HiLoad 1660 Superdex 200 prep grade column and
concentrated and exchanged into 10 mMHepes (pH 7.4)50mM
CaCl2 using a 10-kDa cut-off concentrator unit (Vivascience,
Hannover, Germany). D137A and Y149A were produced and
purified as for the native enzyme, except they were produced
from pD137A- and pY149A-containing E. coli BL21, respec-
tively. Seleno-methionine HylP1 was produced and purified as
for the native protein, except it was produced from E. coli B834
(DE3; Novagen), and 10 mM DTT was incorporated to all
buffers before affinity chromatography. Purity of HylP1 was
judged by SDSPAGE, and static nanospray ion trap mass
spectrometry (LCQ Advantage, ThermoFinnegan, San Jose,
CA) of a tryptic digest was used to confirm the identity of the
protein.
HylP1 Assays. Assays were performed spectrophotometrically at
37°C in triplicate at 232 nm by using a 1-cm pathlength quartz
cuvette containing 2 mgml1 substrate in 50 mMNH4 Ac buffer
(pH 6.5) unless otherwise stated. A molar absorptivity value of
5.5  103 litermol1cm1 was used for concentration calcula-
tions (21). All polymeric substrates, hyaluronan (K salt) from
umbilical cord, chondroitin 4-sulfate (Na salt) from bovine
trachea, and chondroitin 6-sulfate (Na salt) from shark cartilage,
were treated with EDTA and dialyzed extensively before use
(22). The range of hyaluronan concentrations used for deter-
mining kcat and Km values was 1.3–3 mgml1. Goodness-of-fit
statistical analysis of the linear trendlines of the resulting Lin-
eweaver–Burke plots produced R2 values of 0.9935. High-
performance anion-exchange chromatography was performed
according to the method of Lauder et al. (23).
Circular Dichroism (CD). A J-810 spectropolarimeter (Jasco U.K.
Ltd., Great Dunmow, Essex, U.K.) was used for CD analysis of
native and mutant derivatives of HylP1. CD spectra (260–210
nm) averaged from 15 scans were collected at 20°C by using a
bandwidth setting of 3 nm, a scanning speed of 100 nmmin1,
and a 1-mm-pathlength cuvette. Unfolding curves of the proteins
in the presence of 0–5 M guanidinium hydrochloride were
generated by using the 218-nm ellipticity values (see Fig. 5, which
is published as supporting information on the PNAS web site).
The protein concentration used was 4.0mgml1 in 10mMHepes
(pH 7.4)50 mM CaCl2, and the free energy of the folded and
unfolded forms of each protein was determined by least-squares
analysis of the data points from the transition region of the
unfolding curves of the proteins.
Crystallization and Structure Solution. HylP1 was crystallized from
1 l of HylP1 (at 10–20 mgml1) with 1–2 l of the mother
liquor (3.25 M sodium formate); 2-methyl-2,4-pentanediol was
incorporated into the mother liquor to both improve crystal
quality and the ease of freezing. An additional 15% 2-methyl-
2,4-pentanediol was included in the stabilizing solution before
flash freezing in liquid nitrogen. X-ray data were collected from
single crystals at 120 K at the European Synchrotron Radiation
Facility. Multiple anomalous difference (MAD) data were col-
lected on beamline ID 14-EH4 and native data on ID 14-EH1.
X-ray data were processed with MOSFLM (24), with subsequent
computing using programs from the CCP4 suite (25) unless
explicitly stated. Crystals belong to the rhombohedral space
group H32 with the approximate cell dimensions of a b 58.5
Å, c  586.6 Å. The structure was solved by using seleno-
methionine multiple-wavelength data, with final phasing incor-
porating native data. Initial phasing used the seleno-methionine
MAD data, through MLPHARE, with sites determined by using
SHELXD (26). Final phasing incorporated native data, and phases
were subsequently improved and extended to 1.8 Å by using DM
(27) from the CCP4 suite. Five percent of the data were flagged
for cross-validation, and subsequently REFMAC (28) in conjunc-
tion with ARPWARP (29) (both CCP4 suite) were used to build the
sequence into the electron density automatically. QUANTA and
X-FIT (Accelrys, Inc., San Diego) were used to make manual
corrections to the model. Solvent molecules were added using
X-SOLVATE routines of XFIT and checked manually. The final
structure, refined at 1.8-Å resolution, has Rcryst  0.19, Rfree 
0.23 with deviations from stereochemical target values of 0.012
Å for bonds and 1.3° for angles (Table 1).
Fig. 1. Partial genetic map of S. pyogenes prophage SF370.1 and the
hyaluronic acid capsule of streptococci. (a) The gene encoding HylP1 is found
in the region assigned to the phage tail genes, with speC, encoding the phage
supertoxin, located in the region associated with lysogenic conversion. (b) An
electron micrograph of streptococcal cells surrounded by a thick layer of
hyaluronan. Typically, the hyaluronan capsule is one to three times the
diameter of the cell body. The anionic hyaluronan was visualized with cationic
ferritin particles (10 nm) containing electron-dense iron cores. (Scale bar: 1
m, an 27,000-fold magnification.) [Reproduced with permission from Gly-
coforum (www.glycoforum.gr.jp) (Copyright 2004, Glycoforum).] (c) The
-elimination reaction catalyzed by a hyaluronate lyase. This reaction results
in the formation of a 4,5 unsaturated product, which may be detected
spectrophotometrically at 232 nm.








Carbohydrate-active enzymes, notably glycoside hydrolases, car-
bohydrate esterases, glycosyltransferases, and polysaccharide
lyases, have been grouped together into a large number of
sequence-based families. There are almost 100 glycoside hydro-
lase families but merely 15 families of polysaccharide lyase, this
discrepancy reflecting the absolute requirement for uronic-acid
substrates for the latter enzyme class. Prior to this work,
glycoside hydrolase CAZy (http:afmb.cnrs-mrs.frCAZY)
family 69 (GH69) contained 26 ORFs, all from bacteriophage
that infect streptococcal strains (predominantly S. pyogenes but
also S. equi) that were predominantly annotated as hydrolytic
hyaluronidases (EC 3.2.1.35). A feature of this enzyme family is
its very high degree of sequence conservation
Phage Infection of S. pyogenes Involves the Action of an Endo-Acting
Hyaluronan-Specific Lyase. The S. pyogenes M1 group A Strepto-
coccus SF370 virulence factor hyaluronidase, HylP1, was ex-
pressed as a full-length 38.4-kDa N-terminally hexahistidine-
tagged protein. HylP1 is active in the degradation of HA with a
kcat of 7.2 	 0.9 s1 and Km  1.47 	 0.02 mgml1. Increase in
absorbance at 232 nm is consistent with the action of a lyase
(-eliminase) whose action results in the production of a 4,5
unsaturated product (Fig. 1c). The enzyme is not a hydrolase, as
implied by the enzyme commission number, but instead HylP1
[and its sequence homologs such as the S. pyogenes bacterio-
phage H4489A enzyme (17)] are polysaccharide lyases. Conse-
quently, all the former GH69 enzymes have been reassigned to
a new PL family, PL16.
In contrast to the unrelated hyaluronate lyases from group B
streptococci, whose function is the degradation of the host-
organism connective tissue to facilitate pathogen invasion (31–
34), HylP1 is inactive on other connective tissue glycosamino-
glycans such as chondroitin 4-sulfate and chondroitin 6-sulfate.
The in vivo function of HylP1 is further revealed by product
analysis. In stark contrast to the group B streptococcal enzymes,
indeed to any previously characterized carbohydrate-active en-
zymes, the end products of HylP1 digestion of HA are long
oligosaccharides, predominantly HA6 and HA8, with small
amounts of HA4, HA10 and longer (Fig. 2). HylP1 thus has an
endo (random internal cut) mechanism of action with a greatly
extended substrate-binding region, which requires at least four to
six kinetically significant subsites on either side of the cleavage
site. The function of HylP1 is therefore unlikely to be the
complete degradation of connective tissue, or even HA itself.
Instead, it would appear that the role of HylP1 is the introduction
of widely spaced cuts in HA to facilitate a local reduction in
capsule viscosity to aid phage invasion of the bacterial host.
Table 1. X-ray data and structure quality statistics for the S. pyogenes SF370 HylP1
Statistic HylP1 native HylP1 MAD peak HylP1 MAD remote HylP1 MAD inflection
ESRF radiation source ID 14-EH1 ID 14-EH4 ID 14-EH4 ID 14-EH4
Wavelength, Å 0.93400 0.97950 0.93930 0.97960
Resolution of data (outer shell), Å 195.52–1.80 (1.90–1.80) 43.44–2.50 (2.64–2.50) 50.64–2.50 (2.64–2.50) 196.27–2.50 (2.64–2.50)
Rmerge* 0.097 (0.259) 0.062 (0.145) 0.064 (0.223) 0.055 (0.153)
Mean II (outer shell) 14.0 (2.8) 18.3 (7.4) 19.4 (5.2) 19.7 (6.9)
Completeness, % 98.8 (98.8) 99.9 (99.9) 99.9 (99.9) 99.8 (99.8)
Multiplicity 5.5 (4.1) 5.2 (5.3) 5.7 (5.7) 5.0 (5.0)
No. protein atoms 2479
No. ligand atoms 2 (Na ions)
No. solvent waters 267
Rcryst† 0.19
Rfree 0.22
rms deviation 1–2 bonds, Å 0.012
Rms deviation 1–3 bonds, ° 1.346
Avg. protein B, Å2 29
Avg solvent B, Å2 39









Fig. 2. Catalytic activity of S. pyogenes HylP1. High-performance anion
exchange chromatography (see ref. 23) analysis of the products of a digestion
of hyaluronic acid with HylP1 (20 min incubation with HylP1 at 2 gml1).
Identification of hyaluronan oligosaccharides, over a range of time points
from 0 min to 24 h, was achieved by using electrospray mass spectrometry (42)
with the degree of polymerization of product shown. , artifact.
17654  www.pnas.orgcgidoi10.1073pnas.0504782102 Smith et al.
The 3D Structure of HylP1 Reveals a Catalytically Active TSH.The 3D
structure of HylP1 was solved by using three-wavelength multi-
ple-wavelength anomalous dispersion data from a selenomethio-
nyl-derived protein, and harnessing native data to 1.8 Å, HylP1
crystallizes in the H32 (hexagonal setting) rhombohedral cell
with unusual cell dimensions of a b 58.5 Å, c 586.6 Å. The
structure of HylP1 is composed of three intertwined polypep-
tides centered on a crystallographic threefold axis. The structure
(Fig. 3a) can be traced from residue 6 through to the C terminus,
with the sole exception of the loop from Ala-122 to Ser-128,
which is disordered and which may (see below) also be impli-
cated in catalysis. The N-terminal domain (7–35) forms a mixed
globular  capping region that is followed by a coiled region
and segmented -helical coiled-coils to residue 108. The central
‘‘core’’ of HylP1 then follows, a single extended right-handed
TSH in the form of an irregular triangular tube, where each of
the three faces of the tube is composed of alternating -strands
from each of the three polypeptides, with the -strands orthog-
onal to the long axis of the enzyme. The faces of the strands are
deeply concave, contributing to an extended polysaccharide-
Fig. 3. The 3D structure of HylP1. (a) Divergent (wall-eyed) stereoview of HylP1 colored according to chain with the Asp-137Tyr-149 couple shown in cpk
representation (yellow). (b) The TSHs of the bacteriophage T4 gp5 and gp12 proteins and the E. coli K1 bacteriophage poly(2,8-sialidase). HylP1 is unique in
possessing catalytic activity within the TSH itself, in marked contrast to the appended catalytic lysozyme and sialidase of the bacteriophage T4 and E. coli K1
bacteriophage proteins. (c) Close-up of the Asp-137Tyr-149 pair whose mutation renders HylP1 inactive while still maintaining structural integrity. These images
were drawn with MOLSCRIPT (43) and BOBSCRIPT (30).
Fig. 4. The substrate-binding groove of HylP1. (Upper) Electrostatic surface potential of HylP1 (in divergent stereo) revealing an extended substrate binding
cleft that is predominantly positively charged, complementing the negative charge of the substrate hyaluronic acid. (Lower) Complementarity with the
alternating glucuronic acid moieties of the substrate along the putative substrate groove is provided by a ‘‘barber’s pole’’ of positively charged residues (colored
blue) including Arg-163, -190, -216, -277, and -279 and Lys-117, -119, -166, -176, and -226. Asp-137 and Tyr-149 are colored red and green, respectively. This figure
was drawn with PYMOL (http:pymol.sourceforge.net).







binding surface (Fig. 4; discussed below). The TSH of HylP1 is
composed of residues Lys-108 through to Leu-281 and is 65 Å
in length. The repeat on each side of the TSH varies between
8 and 19 residues per turn. At the C terminus of the TSH there
is a short stretch from Ser-282 to Lys-297 where the -sheets do
not intertwine but interdigitate. The remainder of the 220-Å-
long structure is composed of random coil and an -helical
‘‘nose.’’
To our knowledge, the TSH structural element has been
observed in three other bacteriophage tail proteins: the T4 short
tail fiber gp12 (35) and cell-puncturing device gp5 (36) and the
core structure of the E. coli K1 bacteriophage K1F endo-2,8-
sialidase (19). The latter two proteins also are involved in phage
infection of the bacterial host through degradation of the
cell-wall peptidoglycan and capsular polysialic acid, respectively.
Threefold symmetry is thus a feature of tail-fiber proteins,
manifesting itself in another such protein, tailspike gp9 of
bacteriophage P22, except in this case not as a TSH but as three
single-stranded parallel -helices (37). The width of each face of
the triangular tube formed by the HylP1 TSH varies from 49 Å
at the widest point (Asn-274) to 20 Å at its narrowest. Thus, in
contrast to gp5 and gp12, whose shape is regular and ‘‘smooth,’’
the TSH domain of HylP1 is both irregular and concave.
Beyond the simple topology, HylP1 is dissimilar to any re-
ported protein structures (all DALI alignments have Z-scores of
1.2), and all primary sequence alignments of significance
(E-values  1.7) were also of phage-encoded hyaluronate lyases
of S. pyogenes strains. This protein structure is therefore highly
unique and highly specialized to S. pyogenes bacteriophage. The
fact that there is no structural similarity between the TSH
domain of gp5 and gp12 with that of HylP1 and that the
bacteriophage that encode these proteins, T4 and SF370.1,
respectively, belong to different families suggests that the utili-
zation of this structural element by tail-fiber proteins may be an
example of convergent evolution. Indeed, in a topographical, as
opposed to topological, sense, HylP1 is more similar to the
single-stranded parallel -helices of known carbohydrate-active
enzymes such as several pectinases (for example, ref. 38),
chondroitinase B (39), and tailspike gp9 (37). These domains are
irregular, contain grooves, are catalytically active, and, in the
case of gp9, also a component of a noncontractile phage tail.
Catalytic Center of HylP1. Perhaps the single most important differ-
ence betweenHylP1 andTSHdomains observed previously is that
HylP1 catalysis requires no additional catalytic domains, such as the
T4 lysozyme domain appended to gp12 and the bacteriophage K1F
endosialidase (Fig. 3b). We have not obtained complex crystals of
HylP1, but we are able to provide insight into the regions critical for
catalysis. A triple-helical domain-truncated construct, from resi-
dues Asn-106–Asp-310, is catalytically active, confirming that the
catalytic center resides in the TSH domain itself. The TSH
domain provides an extended groove with which to bind long
stretches of HA. Every three to four -strands, positively charged
Arg or Lys residues protrude into this grove, spaced between 9 and
14 Å apart, consistent with the spacing of the negatively charged
glucuronic acid of the alternating GlcA-GlcNAc polymer that is
HA (Fig. 4). Closer inspection of the structure of HylP1 revealed
anAsp–Tyr pair (Fig. 3c), Asp-137, Tyr-149 (adjacent to a loop that
is disordered in the native structure), reminiscent of similar pairings
at the center of structurally unrelated hyaluronate and chondroitin
lyases in which the Tyr residues act as the catalytic base for proton
abstraction from the C5 of the uronic acid with the Asp involved in
pKa maintenance (for example, ref. 40). Tyr-149 is positioned20
and 60 Å from each end of the TSH, consistent with the location
of the active center determined through product analysis. Both
D137A and Y149F mutants are completely inactive, whereas CD
analysis indicated that there are no significant structural differences
between the native and mutant proteins; indeed, the free energies
of the folded and unfolded forms of each protein are also very
similar at approximately1 kcalmol1. We therefore propose that
Asp-137 and Tyr-149 have a catalytic function, but given the length
of the binding groove, we cannot exclude a solely binding role for
these residues.
The unique domain-structure of HylP1, viewed in light of the
gp12 and gp9 structures, allows speculation on a possible orienta-
tion within the phage tail. The N-terminal globular domain of
HylP1 resembles the globular collar domain of gp12 (41). The gp12
globular collar domain is adjacent to its receptor-binding domain,
located at the C terminus of gp12. HylP1 has no such receptor-
binding domain, because the globular domain of HylP1 is at the N
terminus of the enzyme. This distinction is important because it
does not rule out the possibility that there is another protein linked
to HylP1 by means of the N-terminal globular domain, and hence
the tail fiber of SF370.1 may not terminate with HylP1.
HylP1 is a previously undescribed catalytically active TSH
protein. The structure confirms its origins as part of a bacterio-
phage tail assembly whose function is as an ‘‘enzymatic needle’’
that digests the hyaluronic acid capsule during phage invasion of
the S. pyogenes host. The role of HylP1 is not efficient hyaluronan
degradation per se but efficient reduction of the viscosity of
hyaluronan in the immediate vicinity of a single phage particle,
to allow phage penetration to the cell wall. HylP1 has therefore
recruited an extremely long structural protein whose extended
binding surface provides exactly the unusual properties de-
manded for phage penetration of the capsule. The concave sides
of the TSH harness an exceedingly large number of subsites,
which both prevent the enzyme from becoming ‘‘side-tracked’’
by complete degradation of the hyaluronic acid and help avoid
product inhibition. It is particularly significant that the catalytic
center resides within the TSH. It had been assumed, at least
tacitly, that the TSH domain only provided a structural scaffold
onto which catalytic domains were subsequently grafted, as
illustrated by the bacteriophage T4 injection apparatus and the
E. coli K1 phage-encoded sialidase. The HylP1 structure dem-
onstrates that this assumption is not necessarily the case and
suggests that catalytically active TSHs will exist elsewhere.
Given the increasing resistance to conventional antibiotics, we
hope that insight into phage-host specificity and infection pro-
cesses will have an impact on the subsequent design of novel
bacteriophage-derived antibiotics.
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